(Q45751686)

15 December 2017

review article

1 reference

title

Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection (English)

1 reference

15 December 2017

1 reference

Pollard RB

1

1 reference

15 December 2017

Robinson P

series ordinal

2

1 reference

15 December 2017

Dransfield K

series ordinal

3

1 reference

15 December 2017

publication date

1 November 1998

1 reference

15 December 2017

published in

Clinical Therapeutics

1 reference

15 December 2017

volume

20

1 reference

15 December 2017

issue

6

1 reference

15 December 2017

page(s)

1071-1092

1 reference

15 December 2017

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980105-7

7 January 2021

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980105-7

7 January 2021

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980105-7

7 January 2021

Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980105-7

7 January 2021

Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980105-7

7 January 2021

Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980105-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980105-7

7 January 2021

Biologic effects and safety of stavudine: overview of phase I and II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980105-7

7 January 2021

Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980105-7

7 January 2021

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980105-7

7 January 2021

Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980105-7

7 January 2021

Visceral abdominal-fat accumulation associated with use of indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980105-7

7 January 2021

10.1016/S0149-2918(98)80105-7

Identifiers

DOI

1 reference

15 December 2017

1 reference

15 December 2017